See also: Generic Paxil
Paxil CR is a brand name of paroxetine, approved by the FDA in the following formulation(s):
PAXIL CR (paroxetine hydrochloride - tablet, extended release; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: February 16, 1999
Strength(s): EQ 12.5MG BASE [AB], EQ 25MG BASE [AB]
Manufacturer: GLAXOSMITHKLINE
Approval date: December 6, 2000
Strength(s): EQ 37.5MG BASE [RLD][AB]
Has a generic version of Paxil CR been approved?
A generic version of Paxil CR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Paxil CR and have been approved by the FDA:
paroxetine hydrochloride tablet, extended release; oral
Manufacturer: MYLAN
Approval date: June 29, 2007
Strength(s): EQ 12.5MG BASE [AB], EQ 25MG BASE [AB]
Manufacturer: MYLAN
Approval date: April 14, 2011
Strength(s): EQ 37.5MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paxil CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Tablets with controlled-rate release of active substances
Patent 5,422,123
Issued: June 6, 1995
Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
Assignee(s): Jagotec AG
Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
Patent expiration dates:
- June 6, 2012
- December 6, 2012
✓
Pediatric exclusivity
Form of paroxetine hydrochloride anhydrate
Patent 5,872,132
Issued: February 16, 1999
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
"Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Patent expiration dates:
- May 19, 2015
- November 19, 2015
✓
Pediatric exclusivity
Form of paroxetine hydrochloride anhydrate
Patent 5,900,423
Issued: May 4, 1999
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
"Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Patent expiration dates:
- May 19, 2015
- November 19, 2015
✓
Pediatric exclusivity
Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
Patent 6,121,291
Issued: September 19, 2000
Inventor(s): Gleason; Maurice
Assignee(s): SmithKline Beecham plc
This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.
Patent expiration dates:
- March 17, 2017
✓
Patent use: DEPRESSION
- September 17, 2017
✓
Patent use: DEPRESSION
✓
Pediatric exclusivity
Paroxetine hydrochloride form A or C
Patent 6,133,289
Issued: October 17, 2000
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.
Patent expiration dates:
- May 19, 2015
✓
Patent use: DEPRESSION
- November 19, 2015
✓
Patent use: DEPRESSION
✓
Pediatric exclusivity
Controlled release compositions
Patent 6,548,084
Issued: April 15, 2003
Inventor(s): Graham Stanley; Leonard & David Philip; Elder
Assignee(s): SmithKline Beecham plc
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.
Patent expiration dates:
- July 19, 2016
- January 19, 2017
✓
Pediatric exclusivity
Paroxetine controlled release compositions
Patent 7,229,640
Issued: June 12, 2007
Inventor(s): Leonard; Graham Stanley & Elder; David Philip
Assignee(s): SmithKline Beecham p.l.c.
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.
Patent expiration dates:
See also...
- Paxil CR Controlled-Release Tablets Consumer Information (Wolters Kluwer)
- Paxil CR Consumer Information (Cerner Multum)
- Paxil CR Advanced Consumer Information (Micromedex)
- Paroxetine Consumer Information (Drugs.com)
- Paroxetine Consumer Information (Wolters Kluwer)
- Paroxetine Controlled-Release Tablets Consumer Information (Wolters Kluwer)
- Paroxetine Mesylate Consumer Information (Wolters Kluwer)
- Paroxetine Suspension Consumer Information (Wolters Kluwer)
- Paroxetine Consumer Information (Cerner Multum)
- Paroxetine Advanced Consumer Information (Micromedex)
- Paroxetine Hydrochloride AHFS DI Monographs (ASHP)
